FDA’s lack of guidance on biosimilar interchangeability has one sponsor asking others to help push the agency to better define the concept.
The agency does not appear ready to make interchangeability decisions yet
Sandoz Pushing FDA To Make Biosimilar Interchangeability Decisions
Absent guidance, the company says it is submitting proposals for trial designs it believes could demonstrate biosimilar interchangeability.